David Barrett
About David Barrett
David Barrett serves as the Vice President of Cell Biology at Kite Pharma, bringing extensive experience in both laboratory research and clinical application to the development of cellular therapies for cancer. He has contributed significantly to the advancement of Chimeric Antigen Receptor T cells, particularly in the creation of Kymriah, the first FDA-approved gene-modified cell therapy.
Work at Kite Pharma
David Barrett serves as the Vice President of Cell Biology at Kite Pharma, a position he has held since 2022. In this role, he focuses on advancing cellular therapies for cancer, leveraging his extensive background in both laboratory research and clinical application. Kite Pharma is known for its innovative approaches in the field of oncology, particularly in developing gene-modified cell therapies.
Education and Expertise
David Barrett has a robust educational background in the life sciences. He earned a Doctor of Medicine (MD) and a Doctor of Philosophy (PhD) in Human/Medical Genetics from Virginia Commonwealth University, completing his studies from 1997 to 2004. Additionally, he holds a Master of Science (MS) in Biomedical/Medical Engineering from the same institution, achieved between 1995 and 1997. He also obtained a Bachelor's degree in Ecology and Evolutionary Biology from Princeton University from 1991 to 1995.
Background
David Barrett has a diverse professional background, having worked in various roles within the field of medicine and research. He was a Clinical Fellow and later an Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia from 2007 to 2020. His experience includes serving as a Resident Doctor at the same institution from 2004 to 2007. He also held positions at Tmunity Therapeutics Incorporated, including Senior Director of Translational Research and Vice President of Translational Research.
Contributions to Cell Therapy
David Barrett has significantly contributed to the development of Chimeric Antigen Receptor T cells (CART) since 2008. His work was instrumental in the creation of Kymriah, which is recognized as the first FDA-approved gene-modified cell therapy for cancer. This achievement highlights his expertise in advancing innovative therapies that address critical needs in oncology.
Professional Experience
Throughout his career, David Barrett has held various positions that bridge research and clinical practice. His tenure at the Children's Hospital of Philadelphia included roles as an Instructor and Assistant Professor of Pediatrics, where he focused on pediatric care and research. At Tmunity Therapeutics Incorporated, he progressed through several leadership roles, including Executive Director of Translational Research, showcasing his ability to lead and innovate in the field of cellular therapies.